Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI (IRON-RLS)
Intravenous Iron in the Management of Drug-resistant Restless Legs Syndrome: a Randomized Controlled Delayed-start Trial. IRON-RLS
The pathophysiology of restless legs syndrome (RLS) is not well understood: it is thought to involve intracerebral iron deficiency and dopaminergic dysregulation.
This study aims to evaluate the use of intravenous ferric carboxymaltose in patients with restless legs syndrome (RLS).
This study plans to include individuals with RLS, who will be divided into two groups:
- One group will receive intravenous iron immediately after the baseline polysomnography
- The second group will receive intravenous iron 3 months after randomization. In total, participants will be followed for 6 months, during which time they will be required to complete questionnaires regularly, undergo blood draws, and have two polysomnography tests.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Фаза
Фаза
- Фаза 2
Контакты и местонахождение
Контакты исследования
Контакты исследования
- Имя: Yves DAUVILLIERS, MD - PhD
- Номер телефона: 0033 467 3374 78
- Электронная почта: y-dauvilliers@chu-montpellier.fr
Места учебы
-
-
-
Montpellier, Франция
- CHU de Montpellier
-
Контакт:
- Yves DAUVILLIERS, MD PhD
- Номер телефона: 033 4 6733 7478
- Электронная почта: y-dauvilliers@chu-montpellier.fr
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Описание
Inclusion Criteria:
- Age ≥ 18 years;
- Weight ≥ 50 kg;
- Drug-resistant RLS;
- Severe to very severe RLS (IRLSSG-Q score > 20), persistent or recurrent for more than one month;
- Treatment with dopamine agonists without exceeding the recommended doses (ropinirole ≤ 2 mg/day, pramipexole ≤ 0.54 mg/day, rotigotine ≤ 3 mg/day);
- Treatment with dopamine agonists and/or α2δ ligands and/or opioids that has been stable for at least 3 months;
- In cases of sleep apnea syndrome, treatment with continuous positive airway pressure (CPAP);
- Participants were required to be fluent in spoken and written French, be enrolled in a health insurance plan, agree to the automated processing of anonymized confidential data, and have provided written, informed consent for the study.
Exclusion Criteria:
- Iron supplementation (oral or intravenous) within 3 months prior to enrollment and throughout the study period
- Serum ferritin < 50 µg/L or > 300 µg/L;
- Transferrin saturation < 20% or > 45%;
- Hemochromatosis;
- RLS augmentation syndrome ;
- Treatment with neuroleptics or antidepressants;
- Allergy to iron;
- Severe infectious or inflammatory disease within the past 3 months;
- RLS associated with chronic kidney disease, pregnancy, or a clinically significant neurological or psychiatric disorder;
- Severe sleep apnea syndrome (AHI > 30/h) that is untreated, or in cases where treatment is refused or has failed;
- Known allergy, inflammatory, or immune disorder;
- History of severe asthma, eczema, or any other atopic allergy;
- Pregnancy or breastfeeding;
- Also excluded are patients participating in another research study, those deprived of their liberty by judicial or administrative order, those living in a medical facility, those subject to a legal protection order, or those from whom consent could not be obtained.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Immediate treatment
The treatment will be administered at at baseline (V1), immediately after the baseline polysomnography
|
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age
|
|
Активный компаратор: Delayed-onset treatment
The treatment will be administered at 12 weeks
|
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age
|
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
IRLSSG-Q score
Временное ограничение: From Day 0 to Week 12
|
IRLSSG-Q : International Restless Legs Study Group Severity Rating Scale allows for the quantification of the severity of restless legs syndrome
|
From Day 0 to Week 12
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Periodic Limb Movements during Sleep (PLMS) index
Временное ограничение: From V1 (Day 0) to V5 (week 24)
|
The PLMS Index measures the average number of involuntary leg movements per hour of sleeping during polysomnography.
15 or more per hour: Considered abnormal for adults and may suggest a condition called Periodic Limb Movement Disorder (PLMD) if it disrupts your sleep.
|
From V1 (Day 0) to V5 (week 24)
|
|
Total sleep time
Временное ограничение: From day 0 to week 24
|
Total sleep time measured in minutes during polysomnography.
|
From day 0 to week 24
|
|
Sleep latency
Временное ограничение: From Day 0 to week 24
|
Length of time in minutes it takes to transition from full wakefulness to the lightest stage of sleep after the lights are turned off.
|
From Day 0 to week 24
|
|
Sleep time at stage 1-2 during polysomnography
Временное ограничение: From Day 0 to week 24
|
Time spent in stage 1-2 sleep measured in hours and minutes during polysomnography
|
From Day 0 to week 24
|
|
Sleep time at stage 3 during polysomnography
Временное ограничение: From Day 0 to week 24
|
Time spent in stage 3 sleep measured in hours and minutes during polysomnography
|
From Day 0 to week 24
|
|
Micro-awakenings index (MAI)
Временное ограничение: From Day 0 to week 24
|
The Micro-awakenings index measures the number of brief awakenings that the person does not notice per hour of sleep.
|
From Day 0 to week 24
|
|
Apnea-hypopnea index (AHI)
Временное ограничение: From Day 0 to week 24
|
The apnea-hypopnea index (AHI) measures the average number of interruptions or reductions in breathing per hour of sleep to assess the severity of sleep apnea.
|
From Day 0 to week 24
|
|
Average arterial oxygen saturation (SaO2)
Временное ограничение: From Day 0 to Week 24
|
The unit of measurement for SaO2 is the percentage (%).
|
From Day 0 to Week 24
|
|
Oxygen desaturation index (IDO)
Временное ограничение: From Day 0 to week 24
|
The oxygen desaturation index (IDO) measures the number of significant drops in blood oxygen levels per hour of sleep.
|
From Day 0 to week 24
|
|
Serum ferritin
Временное ограничение: From Day 0 to week 24
|
From Day 0 to week 24
|
|
|
Transferrin saturation coefficient
Временное ограничение: From Day 0 to Week 24
|
From Day 0 to Week 24
|
|
|
Epworth Sleepiness Scale (ESS)
Временное ограничение: From Day 0 to Week 24
|
A measure of excessive daytime sleepiness that quantifies the impact of the condition on alertness throughout the day.
Eight everyday situations are rated (for example, watching television, riding as a passenger in a car, sitting quietly in a public place).
Each situation is scored from 0 to 3 based on the likelihood of falling asleep.
Total score 0-24; a score of ≥10 suggests excessive sleepiness
|
From Day 0 to Week 24
|
|
European Quality of Life 5 Dimensions (EQ-5D)
Временное ограничение: From Day 0 to Week 24
|
EQ-5D: this self-administered questionnaire assesses five dimensions (mobility, daily activities, self-care, pain/discomfort, anxiety/depression) as well as overall health status on a visual scale from 0 to 100
|
From Day 0 to Week 24
|
|
Clinical Global Impression (CGI)
Временное ограничение: From Day 0 to Week 24
|
The clinician's overall assessment of the illness, including CGI-S (severity) and CGI-I (change).
7-point scale: CGI-S 1 = normal, 7 = extremely ill; CGI-I 1 = markedly improved, 7 = markedly worsened
|
From Day 0 to Week 24
|
|
Patient Global Impression (PGI)
Временное ограничение: From Day 0 to Week 24
|
Patient's overall perception of the severity of their illness or change; a simple 7-point scale, self-reported.
A high score is associated with patients perceiving their symptoms as severe
|
From Day 0 to Week 24
|
|
Beck Depression Inventory-II (BDI-II)
Временное ограничение: From Day 0 to Week 24
|
BDI-II: a self-administered questionnaire consisting of 21 items that assess the severity of depressive symptoms over the past two weeks; score range: 0-63; thresholds: 0-13 (mild), 14-19 (moderate), 20-28 (severe), ≥29 (severe)
|
From Day 0 to Week 24
|
|
Augmentation Severity Rating Scale (ASRS)
Временное ограничение: From Day 0 to Week 24
|
A 7-item self-administered questionnaire used to quantify the severity of the augmentation syndrome in patients treated with dopamine agonists.
It assesses the worsening or early onset of RLS symptoms and their impact on sleep and daily activities
|
From Day 0 to Week 24
|
|
Insomnia Severity Index (ISI)
Временное ограничение: From Day 0 to week 24
|
To assess the severity of the patient's insomnia, taking into account both the quantity and quality of sleep, as well as its impact on daily functioning (fatigue, concentration, mood).
A 7-item self-report questionnaire scored from 0 to 4, with a total score of 0-28; 0-7 indicates no insomnia, 8-14 mild, 15-21 moderate, and 22-28 severe insomnia
|
From Day 0 to week 24
|
Соавторы и исследователи
Спонсор
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Заболевания нервной системы
- Психические расстройства
- Расстройства сна и бодрствования
- Расстройства сна, внутренние
- Диссомнии
- Парасомнии
- Синдром беспокойных ног
- Качество, доступ и оценка здравоохранения
- Следственные методы
- Эпидемиологический дизайн исследований
- Эпидемиологические методы
- Расширение исследования
- Методы
- Терапия
- Обработка образца
- Клинические лабораторные методы
- Диагностические методы и процедуры
- Диагноз
- Проколы
- Хирургические процедуры, оперативные
- Биопсия
- Сбор данных
- Механизмы оценки здравоохранения
- Качество здравоохранения
- Общественное здравоохранение
- Окружающая среда и общественное здравоохранение
- Контроль поведения
- Иммобилизация
- Диагностические методы, неврологические
- Обследования и анкеты
- Сдержанность, физическая
- Позвоночник
- Случайное распределение
- Трунд карбоксимальтоза
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- RECHMPL25_0557
- 2026-525613-31-00 (Ктис)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .